Can acetazolamide (Diamox) cause deafness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Diamox Cause Deafness?

Acetazolamide (Diamox) can cause tinnitus (ringing in the ears) as a recognized adverse effect, but true deafness or permanent hearing loss is not a documented side effect of this medication.

Understanding the Auditory Side Effects

The FDA-approved drug label for acetazolamide clearly lists tinnitus (ear ringing) as one of the well-recognized adverse reactions that occur most often early in therapy 1. However, the label does not list deafness or permanent hearing loss as an adverse effect 1.

Multiple clinical guidelines consistently identify tinnitus as a known side effect when prescribing acetazolamide:

  • The 2018 consensus guidelines on idiopathic intracranial hypertension specifically warn patients about tinnitus as one of the adverse side effects of acetazolamide, along with diarrhea, dysgeusia (taste alteration), fatigue, nausea, paresthesia, and vomiting 2
  • A 2020 systematic review and meta-analysis of acetazolamide side effects did not identify hearing loss or deafness as a significant adverse event 3

Important Distinction: Tinnitus vs. Hearing Loss

Tinnitus (ear ringing) is NOT the same as deafness or hearing loss. While tinnitus can be bothersome and affect quality of life, it does not represent actual loss of hearing function. The evidence shows:

  • Tinnitus from acetazolamide is typically reversible and occurs early in therapy 1
  • No high-quality evidence links acetazolamide to permanent sensorineural hearing loss
  • In contrast, macrolide antibiotics can cause dose-dependent, reversible sensorineural hearing loss, but this is a different drug class entirely 4

Clinical Context: Acetazolamide in Menière's Disease

Interestingly, acetazolamide has been studied as a treatment for Menière's disease, a condition that causes hearing loss and vertigo. Research shows:

  • Short-term acetazolamide treatment (2-6 weeks) can actually cause a statistically significant decrease in hearing loss in Menière's patients 5
  • However, long-term use (>5 years) does not prevent hearing deterioration in Menière's disease 5
  • This suggests acetazolamide does not cause hearing loss; rather, it may temporarily improve hearing in certain conditions

What to Monitor

When prescribing acetazolamide, you should:

  • Warn patients about tinnitus as a common, reversible side effect that typically occurs early in therapy
  • Advise patients to report any new or worsening ear symptoms
  • Reassure patients that tinnitus usually subsides with dose reduction or discontinuation 1
  • Monitor for other common side effects: paresthesias (most common), dysgeusia, fatigue, nausea, and electrolyte abnormalities 2, 3

Bottom Line

Acetazolamide causes tinnitus, not deafness. If a patient develops true hearing loss while on acetazolamide, investigate other causes rather than attributing it to the medication. The tinnitus associated with acetazolamide is typically transient and resolves with dose adjustment or discontinuation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.